Arbutus Biopharma Corporation (ABUS)

Over the past six months, Arbutus Biopharma Corp.'s stock price has increased by 28.95%. Key events include the release of Q3 2025 financial results, reaffirmation of a "Buy" rating by Chardan Capital, corporate restructuring with workforce reduction and a new CEO, positive clinical trial highlights for imdusiran, ongoing intellectual property litigation, and the reacquisition of greater China rights to imdusiran.

Arbutus Biopharma Corp. does not experience traditional demand seasonality because it is focused on developing new drugs, not selling commercialized products. Its revenue streams are primarily derived from collaborations, licensing agreements, and the achievement of development milestones, which are not subject to seasonal fluctuations in demand.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company focused on developing therapeutics for chronic hepatitis B virus (cHBV) infection. Their major pipeline products include Imdusiran (AB-729), an RNAi therapeutic, and AB-101, an oral PD-L1 inhibitor. The company also researches antiviral medications for coronaviruses and utilizes its Lipid Nanoparticle (LNP) delivery technology.

Arbutus Biopharma Corp. is headquartered in Warminster, Pennsylvania, United States, with operations extending across the United States and Canada.

Arbutus Biopharma's brand reputation is linked to its scientific advancements, clinical trial outcomes, intellectual property protection, and financial stability. The company's reputation is primarily shaped by the progress of its drug candidates, the outcomes of its patent litigation, and its ability to manage its financial resources effectively.

Arbutus Biopharma Corp. has a diverse ownership structure, with institutional investors holding a significant portion of the company's shares. Major institutional owners include Morgan Stanley, Whitefort Capital Management, LP, and BlackRock, Inc. Individual insiders own approximately 1.57% of the company's shares, while the general public holds a substantial portion.